ramosetron has been researched along with Cancer of Rectum in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jeong, SY; Kim, MJ; Kwon, YH; Lee, DW; Lee, MA; Moon, SH; Park, JW; Park, KJ; Ryoo, SB | 1 |
1 trial(s) available for ramosetron and Cancer of Rectum
| Article | Year |
|---|---|
Anterior resection syndrome: a randomized clinical trial of a 5-HT3 receptor antagonist (ramosetron) in male patients with rectal cancer.
Topics: Benzimidazoles; Humans; Male; Middle Aged; Proctectomy; Rectal Neoplasms; Rectum; Serotonin 5-HT3 Receptor Antagonists; Syndrome; Treatment Outcome | 2021 |